Chembio Diagnostics (NASDAQ:CEMI) will collaborate with Takeda (NYSE:TAK) unit Shire Human Genetic Therapies to develop an point-of-care (POC) diagnostic test for an undisclosed biomarker.
The quantitative test will be based on CEMI’s DPP platform and hand-held optical analyzer.
Financial terms are not disclosed.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.